Helen I. Torley is a distinguished leader in the biopharmaceutical industry, currently serving as the President and Chief Executive Officer of Halozyme Therapeutics Inc. With a robust background in pharmaceuticals, Torley has been instrumental in steering Halozyme towards becoming a leader in oncology and drug delivery technologies. Prior to joining Halozyme in 2014, she held significant roles at major companies such as Amgen and Novo Nordisk, where she honed her skills in strategic planning and product development. Her academic credentials include a Bachelor of Science in Biochemistry from the University of Leeds and an MBA from the University of California, Irvine. Under Torley's leadership, Halozyme has seen remarkable growth and innovation. She has successfully guided the company through multiple product approvals and expanded its portfolio, particularly in the field of oncology. One of her notable achievements includes the development and commercialization of ENHANZE® technology, which enhances the delivery of biologics. Torley's strategic vision has also led to numerous partnerships with leading pharmaceutical companies, enhancing Halozyme's position in the market. Her commitment to advancing healthcare through innovative solutions has earned her recognition within the industry and among investors. As President and CEO, Helen I. Torley continues to drive Halozyme's mission to improve patient care through cutting-edge technology. Her role involves overseeing the company's overall strategy, operations, and growth initiatives. Torley's leadership style emphasizes collaboration, scientific excellence, and a patient-centric approach. She remains dedicated to fostering a culture of innovation at Halozyme, ensuring that the company continues to deliver transformative therapies to patients worldwide. Her contributions to the field of biopharmaceuticals and her impact on Halozyme's success make her a pivotal figure in the industry.